Amgen (AMGN) In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued
Amgen (AMGN) In Focus As MariTide Buzz Tests Whether The Stock Is Fully Valued Simply Wall Street
Covered in this story
Analyst targets on Amgen
- RBC Capital Markets: $406 → $430 by Oct 2027 via Pluang
- Cantor Fitzgerald: $406 → $440 by Oct 2027 via AD HOC NEWS
- Truist Securities: $413 → $380 by Oct 2027 · Hold via Investing.com Canada
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 14 Jul 2026.
Summary aggregated from Simply Wall Street's public RSS feed. The full reporting belongs to Simply Wall Street — please read it on their site.